Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13233342 | 0.85 | CA1 (0.49) | CA1CA2MALT1IDO1GAA | |
| SCHEMBL8290128 | 0.84 | HDAC3 (0.55) | CA1CA2 | |
| SCHEMBL13900420 | 0.84 | CA1 (0.48) | CA1CA2MALT1IDO1POLB | |
| SCHEMBL8692644 | 0.84 | POLB (0.55) | CA1CA2GAAPOLBKDM4E | |
| SCHEMBL12472110 | 0.82 | CA1 (0.48) | CA1CA2MALT1IDO1GAA | |
| SCHEMBL9524622 | 0.82 | CYP1A2 (0.59) | CA1CA2POLBLMNAKDM4E | |
| SCHEMBL13936405 | 0.82 | CA1 (0.49) | CA1CA2GAAPOLBKDM4E | |
| SCHEMBL1524995 | 0.81 | LMNA (0.48) | CA1IDO1GAAPOLBLMNA | |
| SCHEMBL6274441 | 0.81 | CA1 (0.58) | CA1CA2IDO1L3MBTL1SIGMAR1 | |
| SCHEMBL5583416 | 0.80 | ALDH1A1 (0.56) | CA1CA2IDO1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263142-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | CAN-FITE BIOPHARMA LTD. (IL) | 2016-09-15 | — | — | US | claimed |
| US-9387220-B2 | Method for inducing hepatocyte proliferation and uses thereof | CAN-FITE BIOPHARMA LTD. (IL) | 2016-07-12 | — | — | US | claimed |
| US-20140364388-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN-FITE BIOPHARMA LTD. (IL) | 2014-12-11 | — | — | US | claimed |
| US-8846635-B2 | Method for inducing hepatocyte proliferation and uses thereof | CAN-FITE BIOPHARMA LTD. (IL) | 2014-09-30 | — | — | US | claimed |
| EP-2227234-B1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN FITE BIOPHARMA LTD (IL) | 2014-05-07 | — | — | EP | claimed |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | The united States of America,as represented by Secretary,Dept.,of Health and Human Services (US) | 2013-05-02 | — | — | US | claimed |
| US-20100249053-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN-FITE BIOPHARMA LTD. (IL) | 2010-09-30 | — | — | US | claimed |
| EP-2227234-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | Can-Fite Biopharma Ltd. (IL) | 2010-09-15 | — | — | EP | claimed |
| WO-2009050707-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | CAN-FITE BIOPHARMA LTD. (IL) | 2009-04-23 | — | — | WO | claimed |
| US-7465715-B2 | Method for treatment of multiple sclerosis | CAN-FITE BIOPHARMA, LTD. (IL) | 2008-12-16 | — | — | US | claimed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | claimed |
| WO-2005063246-A1 | METHOD FOR TREATMENT OF MULTIPLE SCLEROSIS | CAN-FITE BIOPHARMA LTD. (IL) | 2005-07-14 | — | — | WO | claimed |
| EP-1383515-B1 | ACTIVATION OF NATURAL KILLER CELLS BY ADENOSINE A3 RECEPTOR AGONISTS | CAN FITE BIOPHARMA LTD (IL) | 2004-12-15 | — | — | EP | claimed |
| US-20040204481-A1 | Activation of natural killer cells by adenosine A3 receptor agonists | CAN-FITE BIOPHARMA LTD. (IL) | 2004-10-14 | — | — | US | claimed |
| EP-1383515-A1 | ACTIVATION OF NATURAL KILLER CELLS BY ADENOSINE A3 RECEPTOR AGONISTS | Can-Fite Biopharma Ltd. (IL) | 2004-01-28 | — | — | EP | claimed |
| JP-2003514771-A | — | — | 2003-04-22 | — | — | JP | claimed |
| EP-1261322-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ADENOSINE RECEPTOR AGONIST OR ANTAGONIST | Can-Fite Biopharma Ltd. (IL) | 2002-12-04 | — | — | EP | claimed |
| WO-2002083152-A1 | ACTIVATION OF NATURAL KILLER CELLS BY ADENOSINE A3 RECEPTOR AGONISTS | CAN-FITE BIOPHARMA LTD. (IL) | 2002-10-24 | — | — | WO | claimed |
| WO-2001019360-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ADENOSINE RECEPTOR AGONIST OR ANTAGONIST | CAN-FITE BIOPHARMA LTD. (IL) | 2001-03-22 | — | — | WO | claimed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364388-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | HGF, HCAR3, HNF4A | CA1 2046/4885CA2 2577/4885MALT1 4481/4885 |
| US-20160263142-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | ADORA3, ADORA2A, ADORA1 | CA1 1819/4885CA2 2826/4885MALT1 4814/4885 |
| US-20040204481-A1 | Activation of natural killer cells by adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | CA1 4543/4885CA2 3752/4885MALT1 1344/4885 |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | NT5E, NT5C2, NT5C3B | CA1 1948/4885CA2 1174/4885MALT1 3260/4885 |
| US-20100249053-A1 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF | HGF, HCAR3, HNF4A | CA1 2046/4885CA2 2577/4885MALT1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.